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1. Introduction 
The Epstein-Barr virus (EBV) is a globally prevalent γ-herpesvirus that infects over 90% of 
humans and persists for the lifetime of the person. The EB virion is composed of a linear 
dsDNA molecule, an icosahedral capsid, an amorphous tegument, and an envelope 
containing viral glycoprotein spikes on its surface (figure 1A). The EBV primarily infects 
human B-lymphocytes, establishes a latent phase that persists as an incomplete virus, and 
then induces the transformation as well as proliferation of the infected cells. Under certain 
circumstances, latent EBV infection can be reactivated, subsequently giving rise to the 
production of infectious progeny that reinfects cells of the same type. The reactivated virus 
can also be transmitted to another individual. 1 
EBV-infected B lymphocytes harbor the latent EBV genome as a multicopy episome. There is 
compelling evidence that most EBV-associated malignancies have escaped this potent virus-
specific cytotoxic T-lymphocytes (CTL) response by restricting viral gene expression. EBV 
expresses more than 80 lytic antigens, whereas latent EBV does not produce progeny 
virions. However, latent EBV expresses a limited set of viral gene products that maintain the 
viral genome as well as promote host-cell survival and proliferation. Latent EBV-infected 
cells express up to nine proteins (figure 1B) and several non-translated RNAs.2 Among the 
nine latent EBV proteins, six are EBV nuclear antigens (EBNA1, 2, 3A, 3B, 3C, and LP) and 
three are latent membrane proteins (LMP1, 2A, and 2B). Based on the latent viral gene 
expression pattern, the latency is characterized as three main types, namely, types I, II, and 
III.3 A type I infected cell only expresses EBNA1; EBNA1, LMP1, and LMP2 are found in 
type II infected cells. A type III infected cell expresses the full spectrum of latent EBV 
proteins.  
The role of the immune system in the defense against EBV-associated diseases has recently 
become a popular topic. One hypothesis suggests that numerous neoplasms express viral 
antigens that should potentially enable them to be recognised and destroyed by the immune 
system. The EBV infection of B cells is mainly controlled by CD8+ T cells, in addition to 
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natural killer (NK) cells. CD4+ T cell response is also probably important as a source of 
either effector cells or cytokine help for the massive CD8+ T cell.4  
 
A. 
 
 
B. 
 
Fig. 1. A) Structure of EB virion. B) Schematic diagram of the EBV genome and location of 
nine genes expressing latent proteins. The location and polarity of the EBV nuclear antigens 
(EBNAs) encoding region are shown with blue arrows, latent membrane proteins (LMPs) 
encoding region are shown with red arrows.  
www.intechopen.com
 
Vaccines and Antiviral Drugs for Diseases Associated with the Epstein-Barr Virus  
 
243 
2. EBV-associated diseases 
EBV is best known as the aetiological agent of infection mononucleosis (IM), which is most 
common among adolescents and young adults. IM, a self-limiting disease, is characterised 
by the appearance of heterophile antibodies in the serum and an atypical lymphocytosis.5 In 
developing countries, people are exposed to the virus in their early childhood when they are 
unlikely to produce noticeable symptoms. In developed countries, such as the United States, 
the age of first exposure may be delayed to late childhood and young adulthood age when 
symptoms are more likely to manifest.  
2.1 EBV-associated cancers 
EBV is associated with an increasing number of lymphoproliferative processes and 
epithelial neoplasias not only in immunodepressed or immunodeficient patients, but also in 
immunocompetent persons. EBV-related tumors are characterised by the active expression 
patterns of viral gene products (Table 1). 
 
 IM BL HL NPC PTLD 
EBNA1 + + + + + 
EBNA2 + _ _ _ + 
EBNA3A + _ _ _ + 
EBNA3B + _ _ _ + 
EBNA3C + _ _ _ + 
EBNALP + _ _ _ + 
LMP1 + _ + + + 
LMP2A + _ + + + 
LMP2B + _ + + + 
EBERs + + + + + 
BARTs + + + + + 
Latency III I II II III 
Table 1. Expression pattern of latent EBV infected genes in EBV- related diseases. IM: 
infection mononucleosis; BL: Burkitt’s lymphoma; HL: Hodgkin’s lymphoma; NPC: 
Nasopharygeal carcinoma; PTLD: Posttransplantation lymphoproliferative disorder. 
Burkitt’s lymphoma (BL), first described by Denis Parsons Burkitt in 1956, are classified into 
three forms: endemic, sporadic, and AIDS-associated BL.6 Endemic BL,  initially found in 
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Africa, is the most common childhood lymphoma in western countries and accounts for 
approximately 5% of all adult lymphomas.7 About 97% of endemic BL patients are EBV-
positive, suggesting the strong association of endemic BL with EBV. On the other hand, EBV 
DNA can be detected in 20%-40% of sporadic and AIDS-associated BL.6 EBNA1 is the only 
EBV antigen expressed in BL. 
Hodgkin’s lymphoma (HL) has first been described by Thomas Hodgkin in 1832.8 
Approximately 25%-50% of classical HL cases are associated with the presence of EBV in 
Reed-Sternberg (RS) mononuclear, and multinuclear cells,9 which are major components 
of the tumor.10 RS cells produce cytokines and chemokines, including TGF-B, IL-10, and 
TARC. These cytokines and chemokines possibly enable RS cells to modulate the immune 
response and escape CTL detection.11 The human tumor-associated antigen RCAS1 
expressed in RS cells induces the apoptosis of activated cytotoxic T cells and natural killer 
(NK) cells. EBV-positive RS cells expressing RCAS1may evade the host immune 
response.12  
Nasopharygeal carcinoma (NPC), the most common tumor that develops in the 
nasopharynx, is extremely common in Southeast Asia and Africa.13 The EBV genome has 
been coincidentally found in all NPC specimens,14 i.e. NPC shows a 100% association with 
EBV. The latent EBV gene expression pattern in NPC is generally very similar with that 
detected in most EBV-related HL cases. However, there is no detectable IL-10 and TARC 
expression in NPC tumor cells, suggesting that the mechanism for escaping immune 
recognition and destroying NPC tumor cells is different from HL.11 LMP1 is known to have 
oncogenic properties during latent infection in NPC, and is thought to be a key modulator in 
the pathogenesis of NPC.13 LMP1 triggers the NF-κB, AP-1, and STAT signaling pathways in 
NPC. Ultimately, all signaling cascades triggered by LMP1 lead to the disruption of the cell 
cycle, inducing cell transformation.13 
Posttransplantation lymphoproliferative disorder (PTLD) is an uncontrolled proliferation of 
B lymphocytes occurring in immunocompromised patients following organ transplant with 
immunosuppressant medication.15 The relationship between EBV and PTLD has first been 
noted by Crawford et al. in 1980.16 PTLD has a complex clonal diversity ranging from 
polymorphic B-lymphocyte hyperplasia to malignant monoclonal lymphoma.5 The B-
lymphoma cells of PTLD patients express a full spectrum of latent EBV genes.17 
In HIV-associated lymphomas, the HIV-induced immunodeficiency may increase the traffic 
of EBV-infected B-cells,  leading to a wide variety of AIDS-related lympholmas.18 the 
incidence of non-HL (NHL) in AIDS has increased. Primary cerebral lymphoma (or primary 
central nervous system lymphoma), a form of NHL, is strongly related to EBV because EBV 
DNA is present in cerebrospinal fluid. 
2.2 EBV-associated autoimmune diseases 
There is increasing evidence that EBV is a possible triggering factor of many human-
autoimmune diseases.19 
Multiple sclerosis (MS) is a neurological disease characterised by chronic inflammation and 
demyelination within the central nervous system. A higher frequency of EBV seropositivity 
and a higher prevalence of high anti-EBV antibody titres exist in patients with MS compared 
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with controls.20 About 99% of MS patients are EBV-seropositive.21 To determine whether 
antibodies to EBV are elevated before the onset of MS, Levin et al. have conducted a study 
on the blood samples of  more than three million US military personnel. The results 
demonstrate that the presence of high EBV antibody titres in human increases the risk for 
developing MS by 34-fold.22 Although there is no sufficient evidence to conclude that EBV 
virus causes MS, in some cases, the first attack of MS occurrs at the time of primary EBV 
infection.23 Apparently, T cells controlling EBV-infected B cells in MS patients are 
impaired.24 
Systemic lupus erythematosus (SLE), an autoimmune chronic inflammatory disease that 
generates a multi-systemic rheumatic disorder, which ultimately causes organ failure.25 
Compared with controls, SLE patients have increased EBV viral load,26 anti-EBV antibody 
levels27, and numbers of latently infected peripheral B cells. The functional T cell responses 
of SLE patients are also impaired, and they are positive for the presence of EBV DNA. About 
99% of young SLE patients are EBV seropositive.26  Verdolini et al.28 have reported a 22-
year-old woman who immediately developed SLE after contracting EBV- induced IM. The 
data obtained from this case suggest that EBV infection can work as a trigger of SLE in some 
cases, particularly if the patient is genetically susceptible. The T cells controlling the EBV-
infected B cells in SLE become defectived that cannot control the numbers of EBV-infected B 
cells.29 
Rheumatoid arthritis (RA) is a widespread autoimmune disease characterized by the 
infiltration of CD4+ T cells and NK cells into synovial joints.30 Compared with controls, RA 
patients exhibit increased viral load, anti-EBV antibody titres, and frequency of circulating 
EBV-infected B cells.31 The high frequency of EBV-infected B cells in RA patients may be 
explained by the impaired control of infected B cells by EBV-specific T cells.32  
Sjögren’s syndrome is an autoimmune disorder characterised by lymphoid infiltrates in the 
salivary gland. Patients with this disorder have elevated levels of anti-EBV antibodies33 and 
decreased EBV-specific T cell cytotoxicity.34  
Other autoimmune disorders, such as autoimmune thyroid disease,35 scleroderma,36 
autoimmune liver disease (primary biliary cirrhosis and autoimmune hepatitis),37 
inflammatory bowel disease (ulcerative colitis and Crohn’s disease),38 as well as cryptogenic 
fibrosing alveolitis39 are also associated with EBV. Patients with any of these disorders all 
have increased EBV DNA loads and increased serum levels of anti-EBV antibodies. 
3. Vaccines 
EBV is known to be associated with a large number of human malignancies in 
immunocompetent and immunosuppressed individuals. Prophylactic vaccines against some 
pathogenic viruses are excellent public health interventions in terms of safety and 
effectiveness. Accordingly, there is a great demand for effective vaccines against EBV. 
Interest in formulating an effective vaccine against EBV is increasing, but onlt a few clinical 
trials have been conducted. No candidate vaccine has yet been proven sufficiently effective 
as to warrant commercialisation.  
Vaccines should be able to either block primary EBV infection or significantly reduce the 
EBV load during primary EBV infection. Almost all, if not all, EBV-associated malignancies 
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develop years after the primary EBV infection. Given that immunisation with whole viral 
proteins does not elicit an efficient CTL response, focus has been directed towards 
developing peptide vaccines based on defined epitope sequences. Two broad approaches 
being considered to design effective vaccines for controlling EBV-associated diseases are 
discussed in the following subsections. 
3.1 EBV structural antigens as target antigens 
The EBV is enveloped by a membrane composed of four major virus-specific proteins, 
namely, gp350, gp220, gp85, and p140.40 The EBV mainly binds to B cells, via the interaction 
of the gp220 present in the envelope of the virus with cell receptor CD21. This interaction 
fosters infection. Later, the EBV produces a latent infection mainly in B cells.41 Most 
strategies for developing EBV vaccines have focused on the virus membrane antigen, which 
consists of at least three glycoproteins.  
Prophylactic vaccines are known to function primarily via the induction of virus-
neutralising antibodies. Gp350 contains the main neutralisation epitope and is the primary 
target of the virus-neutralising antibody response. These features suggest that gp350 is a 
primary potential vaccine candidate. In the past several decades, there have been several 
efforts of developing vaccines mainly focused on the use of a subunit preparation of gp350 
(recombinant and affinity purified). Abundant recombinant formulations of gp350 
presenting as a subunit antigen or expressing from recombinant viral vectors, generated to 
induce high load neutralising antibodies, have shown significant protection against EBV-
induced B-cell lymphomas in cotton-top tamarins. The recombinant gp350 vaccine is able to 
elicit neutralising antibodies in a phase I/II trial,42 has a good safety profile, and is well 
tolerated.43 The vaccine is proven effective in preventing the development of EBV-induced 
IM, but has no efficacy in preventing asymptomatic EBV infection.44 Indeed, highly purified 
gp350 induces high levels of neutralising antibodies and inhibits tumor formation in cotton-
top tamarins when administered subcutaneously administered with adjuvants such as 
muramyl dipeptide or immune-stimulation complexes,.45 A number of recombinant vectors, 
including vaccinia-gp350 and adenovirus 5-gp350, have also been successfully used in these 
animals to block tumor outgrowth.46 Nevertheless, the development of neutralising 
antibody titres in vaccinated animals does not always correlate with protection.47 Yao et al. 
have demonstrated that very low levels of neutralising anti-gp350 antibodies are present in 
the saliva of healthy EBV-immune donors. This finding suggests that such antibodies are 
unlikely to be the basis of long-term immunity in healthy seropositive individuals.48 
Apparently, a vaccine solely based on gp350 does not completely prevent the infection of 
every single B lymphocyte or epithelial cell.  
Wolf et al.49 have expressed poly-antigens containing several antigenic determinants of 
gp220 and gp350. These proteins are useful in the prophylaxis and therapy of EBV-related 
diseases because they are able to modulate the immune responses of patients suffering 
from diseases such as NPC, IM, or EBV-related BL. Mond et al.50 have enhanced B-cell 
activation and immunoglobulin secretion by co-stimulation of the receptor for antigen 
gp350/220. 
gp85 is also a potential target for vaccine design.51 Burrows et al.52 have successfully 
identified CTL epitopes within the EBV structural antigen gp85. Using ex vivo primary 
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effectors, strong reactivity to gp85 peptides is observed. An animal model system further 
reveals that gp85 epitopes are capable of generating structural antigen-specific CTL 
responses and reducing infections with the virus expressing gp85. Queensland Institute of 
Medical Research has developed a vaccine including several CTL epitopes that provides 
protection to more than 90% of the Caucasian population.53 In 1995, the recombinant 
vaccinia virus expressing the major virus membrane antigen has first been used in 
humans.54 
3.2 Latent antigens as potential vaccine candidates 
EBV structural antigens are not expressed in latently infected B-lymphocytes. Hence, 
therapeutic EBV vaccine efforts have been focused on latency antigens expressed in EBV-
associated diseases. EBNA1 has been identified as a vaccine antigen. In a specific 
embodiment, a purified protein corresponding to EBNA1 elicits a strong CD4+ T cell 
response.55 Another vaccine for EBNA2 with the aim of treating and/or preventing PTDL 
has been developed.56 LMP1 and LMP2 are the only target antigens available for expanding 
CTL responses in patients with HD and NPC. Duraiswamy et al.57 have generated a 
recombinant poxvirus vaccine that encodes a polyepitope protein derived from LMP1. 
Human cells infected with the vaccine are efficiently recognised by LMP1-specific CTLs 
from HLA A2 healthy individuals. The outgrowth of LMP1-expressing tumors in HLA 
A2/Kb mice is also reversed by the vaccine. 
EBNA1 is a protein expressed during both the latent and lytic phases of the EBV. EBNA1 is 
the only viral protein expressed in all EBV-positive proliferating cells in healthy EBV 
carriers and in all EBV-associated malignancies.58 Therefore, a possible vaccine would 
include EBNA1 added to another latent or lytic gene. A group has developed a vaccine 
comprising a synthetic polypeptide with a plurality of different segments of parent EBV 
polypeptides, including EBNA1, LMP1, and LMP2.59 The vaccine is mainly aimed at treating 
NPC, HL, and PTLD. Taylor et al. 60 have generated a modified vaccinia virus Ankara 
recombinant, MVA-EL, which expresses the CD4+ epitope-rich C-terminal domain of 
EBNA1 fused to full-length LMP2. LMP2 is the source of subdominant CD8+ T cell epitopes. 
MVA-EL has immunogenicity to both CD4+ and CD8+ T cells. 
4. Antiviral drugs 
4.1 Targeting lytic DNA replication/EBV-encoded DNA polymerase 
Lytic phase EBV causes a cell-to-cell infection in the same host or transmits the virus to 
another individual. Until now, the most successful therapeutic interventions used against 
EBV infection and its associated diseases target the lytic replication of EBV. 
DNA polymerase performs a key step in DNA replication. The polymerase ‘reads’ an intact 
DNA strand as a template and uses it to synthesise the new strand. During the lytic phase of 
the EBV life cycle, EBV DNA polymerase mediates viral DNA replication. Compounds that 
target EBV DNA polymerase are used to treat diseases associated with lytic EBV infection, 
and are widely used in various clinical settings. Drugs that may be possible candidates for 
targeting viral DNA polymerase are categorised into two groups, namely, nucleoside 
analogues and non-nucleoside DNA polymerase inhibitors. 
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4.1.1 Nucleoside analogues 
Nucleosidic antivirals have been used in the clinical treatment of EBV-associated diseases 
since the late 1970s. Acyclovir (ACV; 9-(2-hydroxyethoxymethyl) guanine), a synthetic 
acyclic nucleoside compound, has been initially shown to have a potent inhibitory activity 
against herpes simplex virus (HSV) infected cells.61 Subsequently, ACV has been proven as 
an effective inhibitor of viral DNA replication in lytic EBV-infected cells, but without the 
same function in latently infected ones.62 Given that ACV is only effective in the lytic phase 
by selectively inhibiting EBV DNA polymerase, efficacious compounds urgently need to be 
developed. Nucleoside analogues are prodrugs that require phosphorylation by viral 
thymidine kinase to become active. Inspired by ACV, nucleoside analogues such as 
ganciclovir (GCV; 9-(1,3-dihydroxy-2-propoxymethyl) guanine)63 and penciclovir (PCV; 9-
(4-hydroxy-3-hydroxymethylbut-1-yl) guanine),64 as well as nucleotide analogues including 
cidofovir (CDF; (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine)65 and adefovir (9-
(2-phosphonylmethoxyethyl) adenine, PMEA)66 have been developed. GCV reduces the risk 
of EBV-associated PTLD in renal transplant recipients, and may be more efficacious than 
ACV.67 The inhibitive activity of PCV to EBV has also been evaluatedin assays, wherein 
infectious virus production, viral antigen expression, and viral DNA synthesis are 
measured. The obtained data suggest that PCV is a selective inhibitor of EBV in cell 
cultures.68 CDF, an acyclic nucleoside phosphonate analogue, decreases EBV oncopreteins 
and enhances radiosensitivity in EBV-associated diseases.69 In vitro, adefovir is a potent 
inhibitor against a few viruses including EBV.70Nevertheless, efficiencies of these 
compounds as inhibitors of EBV are limited. To improve bioavailability, the orally available 
prodrugs valaciclovir (VACV),71 valganciclovir (VGC; the valine ester of GCV)72 and 
famciclovir (FCV)73 have been introduced in the mid-1990s. VACV, the L-valyl ester of ACV, 
is rapidly and almost completely converted to ACV in vivo, as well as provided three to five 
times increase in ACV bioavailability.74 The pharmacokinetics of the orally administered 
VGC, the valine ester of GCV, has been studied compared with the pharmacokinetics of oral 
and intravenous GCV. VGC results in the improved oral absorption of GCV in liver 
transplant recipients.75 FCV, the oral form of PCV, is converted to PCV in vivo.76 Despite the 
impressive efficiency of these nucleoside analogues in the treatment of herpes simplex 
infection, all these compounds suffer from the same drawbacks, including toxic side effects, 
poor oral bioavailability, and potential mutagenesis. Nearly all clinically effective nucleoside 
analogues also target the same active sites on viral DNA polymerase molecules, such that 
mutant viruses resistant to one drug are commonly resistant to others.77  
4.1.2 Non-nucleoside inhibitors 
Given the success of ACV and its analogues, additional inhibitors of DNA polymerases have 
been expectedly identified. For example, foscarnet (the trisodium salt of phosphonoformic 
acid),78 apparently inhibits EBV replication within the range of 2μM to 3μM, which is 
nontoxic to normal cellular growth. The inhibitory effects of foscarnet are exerted at the 
pyrophosphate binding site of DNA polymerase. Given that foscarnet is not activated by 
viral kinases, it is often used as an alternative treatment for EBV, and forACV- or GCV-
resistant patients. However, foscarnet is more toxic than ACV, has profound metabolic side 
effects, and must be intravenously administered.77 A novel class of non-nucleoside 
inhibitors against DNA polymerases, 4-oxo-dihydroquinolines (represented as PHA-529311 
and PHA-570886), has great inhibitory activity against multiple herpesviruses. These 
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inhibitors also show activity against ACV-resistant HSV and varicella-zoster virus isolates, 
as well as GCV- or foscarnet-resistant cytomegalovirus isolates.79  
4.2 Targeting latent infections/EBV-encoded latent proteins 
Most EBV-associated tumors harbor the latent viral genome as a multicopy episome in the 
nucleus of the transformed cells. During latent infection, the EBV does not produce progeny 
virions, but expresses a limited set of viral gene products that promote host-cell survival 
and proliferation. The EBV-encoded proteins involved in latency that have received the 
most attention are EBNA1, EBNA2, EBNA3A, EBNA3C, LMP1, and LMP2A. These latent 
proteins can induce the immortalisation and proliferation of infected cells, and are 
involveed in immune response evasion, which are essential for neoplasias. 
4.2.1 LMP1 as a target protein 
LMP1 is an integral membrane protein containing a short N-terminal cytoplasmic tail of 17 
amino acids, 6 hydrophobic transmembrane-spanning domains, and a large cytoplasmic C-
terminal domain of 200 amino acids.80 LMP1, is the main transforming protein of EBV, is 
identified as the principal oncoprotein because it can transform rodent fibroblasts and is 
essential for the immortalisation of B cells.81 LMP1 is a functional homologue of the TNF 
receptor CD40, which that can deliver a signal to rescue cells from apoptosis and drive 
proliferation.82 LMP1 mimics CD40 in activating multiple downstream signaling pathways, 
such as the NF-κB and JNK pathways, Subsequently, LMP1 up-regulates the expression of 
cellular genes involved in cell proliferation, cytokine secretion, angiogenesis, and tumor 
metastasis.83 The expression of LMP1 induces EBV-associated lymphomas in transgenic 
mice.84 Based on these characteristics, LMP1 is a potential target for EBV-associated diseases.  
Antisense oligonucleotides (AODs) are effective in inhibiting gene expression in a sequence-
specific manner.85 A number of research groups have used antisense molecules for silencing 
LMP1. This process is performed with the notion of modulating the course of EBV- 
associated lymphoproliferative disorders because the modulation is vital for B-cells 
transformation. As expected, silencing the expression of LMP1 rendered the EBV-positive 
lymphoblastoid cell lines susceptible to chemotherapeutic agents by abrogating Bcl-2 
upregulation and consequently enhancing apoptosis.86 Galletti et al.87 have examined the 
efficacy of liposomes, dendrimers or transferrin–polylysine-conjugated oligonecleotides 
(ONs) for antisense molecules. The data have indicated that only the delivery system 
exploiting the transferrin receptor pathway internalised active molecules for silence LMP1 
expression. Intracellular single-chain antibodies (sFvs), the smallest domain region of an 
antibody that retains the binding specificity of the parental antibody, could selectively 
knockout viral or cellular oncoproteins. Piche et al.88 have reported that an anti-LMP1 sFv 
increases the sensitivity of EBV-transformed B lymphocytes to drug-induced cell death. The 
authors suggest that an anti-LM1 sFv used in combination with conventional chemotherapy 
may be useful for the therapy of EBV-related lymphomas in immunocompromised patients.  
4.2.2 LMP2A as a target protein 
LMP2A can promote the survival of latently infected cells and prevent EBV reactivation 
from the latent phase to the lytic phase.89 LMP2A signaling does not cause B cells to grow, 
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but delivers a critical signal that is essential for the survival of all B cells.82 In in vitro 
infected B cells, the LMP2A N-terminal cytoplasmic domain blocks B cell antigen receptor 
(BCR) signal transduction, preventing the change from the latent to the lytic cycle, thereby 
maintaining latency.90 This domain interacts with Syk and Lyn protein tyrosine kinases via 
multiple phosphotyrosines arranged in ITAM- and SH2-protein binding motifs. Hence, Syk 
and Lyn are prevented from binding to the cytoplasmic B cells. Syk and Lyn binding to 
cytoplasmic B cells are able to induce the lytic cycle.  
Monroe et al.91 have used peptide homologues (synthetic ITAM analogues) to inhibit the 
interaction of proteins and the ITAM-protein binding motif of viral proteins. They have 
shown that the blocking association of LMP2A ITAM with cellular molecules and the block-
ing of LMP2A ITAM-mediated signaling are effective strategies for the treatment and 
prevention of metastases of EBV-induced malignancies.  
4.2.3 EBNA1 as a target protein 
EBNA1 is an extremely attractive target for preventing EBV infection and treating EBV-
related malignancies.  EBNA1 is the only viral protein expressed in all EBV-positive 
proliferating cells in healthy EBV carriers and in all EBV-related malignancies.92 EBNA1 is 
essential for the persistence of the EBV episome, and is anti-apoptotic in contributing to 
infected-cell survival.93 EBNA1 also has well-defined biochemical and structural properties. 
It consists of several functional domains, including a well-defined carboxyl-terminal DNA 
binding domain.94 This domain is essential for interacting with the viral oriP. OriP 
consisting of a series of 30 bp repeats acts in cis to permit linked DNAs to replicate as 
plasmids in cells containing EBV DNA. EBNA1 regulates the function of oriP to which 
EBNA1 binds an 18 bp palindromic-sequence as a homodimer.95 The DNA binding and 
dimerisation interface have been solved by high resolution X-ray crystallography in the apo- 
and DNA-bound forms.96  
The approach of using an AOD to target a single selected viral gene product is promising for 
the treatment of EBV infections.97 The treatment of EBV-transformed B cells with EBNA1 
antisense ONs inhibits the proliferation of EBV-immortalised cells by at least 50% compared 
with scrambled antisense sequences.98 In contrast to primary B cells, EBV-transformed B 
lymphoblastoid cell lines express alpha-v integrins, the adenovirus internalisation receptor, 
and are also susceptible to adenovirus-mediated gene delivery. The adenovirus delivery of a 
specific EBNA1 ribozyme to lymphoblastoid cell lines as well as suppressed EBNA1 mRNA, 
and protein expression, significantly reduce the number of EBV genomes.99 Recently, Sun et 
al.100 have demonstrated that Hsp90 inhibitors can be used to inhibit EBNA1 expression and 
translation. This effect requires the EBNA1 Gly-Ala repeat domain. Hsp90 inhibitors induce 
the death of established, EBV-transformed lymphoblastiod cell lines at doses that are 
nontoxic to normal cells. Hsp90 inhibitors prevent the EBV transformation of primary B cells 
and strongly inhibit the growth of EBV-induced lymphoproliferative disease in severe 
combined immunodeficiency (SCID) mice. The authors suggest that Hsp90 inhibitors may 
be particularly effective for treating EBV-induced diseases requiring the continued presence 
of the viral genome. Li et al.101 have identified a new class of small molecule compound 
inhibitors of EBV latent infection based on their ability to inhibit the DNA binding function 
of EBNA1. The molecules have been discovered via high throughput in silico virtual 
screening and further validated by biochemical as well as cell-based assays. Four 
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compounds are identified to have biochemical activity, and two of which have activity in 
cell-based assays.  
4.2.4 EBNA2 and EBNA3 as target proteins 
EBNA2 is related to the differentiation and transformation of B cells. EBNA2 acts as a trans-
activator molecule that binds to cellular sequence-specific DNA-binding proteins, such as 
the Jkappa recombination signal binding protein (CBF1/RBP Jkappa). Consequently, the 
cellular genes CD23 and CD21, as well as the viral genes LMP1 and LMP2A are 
transactivated.102 However, EBNA3A and 3C can inhibit EBNA2 activation of transcription 
by interacting with RBP Jkappa.103 EBNA3A and 3C, other than EBNA3B, are critical to this 
B-lymphocyte growth transformation.104 Farrell et al.105 have synthesised a 10-aa peptide 
from the CBF1 interaction domain of EBNA2 as a fusion with the protein transduction 
domain of HIV-1 TAT (transcriptional transactivator). Treatment of an EBV-immortalised 
lympfoid cell lines (LCLs) with the EBNA2-TAT peptide stops cell growth and reduces cell 
viability. EBNA2-TAT peptide treatment also down-regulats the viral LMP1 and LMP2 
genes as well as cellular CD23 expression while up-regulating the expression of the cyclin-
dependent kinase inhibitor p21. As another form of treatment, Kempkes106 has provided a 
mutant RBP-J DNA binding protein capable of binding the Notch protein but unable to bind to 
EBNA2. The RBP-J DNA binding protein presents an amino acid sequence with at least one 
mutation in the EBNA2 binding domain, thereby preventing immortalisation. EBNA3C 
regulates cell cycles by targeting critical cellular complexes such as cyclin A/cdk2, SCFSkp2, 
and Rb. Knight et al.107 have used a 20-aa EBNA3C-derived peptide fused to an HIV TAT-tag 
to disrupt the EBNA3C-mediated cell cycle. The peptide has inhibited a hyperproliferation of 
EBV-infected B cell lines and reduced in vitro immortalization of primary B lymphocytes by 
EBV. The peptide also inhibited lymphoblastoid outgrowth from the blood of an EBV-positive 
transplant patient in vitro.These experiments suggest that inhibitors targeted against EBNA2 
and EBNA3C may be have potential novel anti-EBV therapeutics. 
5. Therapies 
Chemotherapies based on chemical products play important roles in the treatment of EBV-
associated diseases. Immunotherapies using antibodies, such as the anti-CD30 and anti-
CD20 antibodies (rituximab) are used to treat EBV-related malignancies. Rituximab has been 
combined with standard chemotherapy for EBV-associated diseases, with promising 
results.9, 108 Other therapies such as adoptive immunotherapy, gene therapy and small 
interfering RNA (siRNA) therapy have also been developed. 
5.1 Adoptive immunotherapy 
The adoptive transfer of antigen-specific cytotoxic T lymphocytes offers a safe and effective 
therapy for certain viral infections and could prove useful in the eradication of tumor cells. 
Helen et al.109 have reported the long-term detection of gene-marked EBV-specific CTLs in 
immunocompromised patients at risk for the development of EBV lymphoproliferative 
disease. Infusions of T cell lines have not only restored cellular immune responses against 
EBV, but have also established populations of CTL precursors that could respond to in vivo 
or ex vivo challenge with the virus for as long as 18 months. The adoptive transfer of EBV-
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CTLs has been successfully applied in the treatment of PTLD. In 2010, Helen et al.110 have 
tried to address the long-term efficacy, safety, and practicality of EBV-specific CTL 
immunotherapy. They have studied 114 patients who received infusions of EBV-specific 
CTLs to prevent or treat PTLD. None of the 101 patients who received CTL prophylaxis has 
developed EBV-positive PTLD, whereas 11 of the 13 patients treated with CTLs for biopsy-
proven or probable PTLD have achieved sustained complete remissions. A gene-marking 
component is used to demonstrate the persistence of functional CTLs for up to 9 years. The 
conclusion is that CTL lines provide a safe and effective prophylaxis or treatment for PTLD.  
However, Subklewe et al111 compared dendritic cells (DCs) with LCLs for T cell stimulation 
against dominant and subdominant EBV antigens. DCs expand tenfold more EBNA3A and 
LMP2 specific T cells than LCLs, and expand EBV-specific T cell responses more efficiently 
than LCLs. In a specific embodiment, a vaccine using DCs charged with EBNA1 elicits a 
strong T cell response.112 Kuzushima et al.113  have introduced EBNA1 and LMP1 mRNAs 
into APCs. These modified cells can induce EBV-specific CTLs, inhibit the outgrowth of 
EBV-infected B lymphocytes, and then lyse EBV-infected NK lymphomas and NK cells.  
5.2 Gene therapy 
Gene therapy strategies for introducing novel compounds or cytotoxic gene products (e.g., 
HSV1-TK gene into EBV-infected tumor cells followed by GCV therapy) are being actively 
developed. Such strategies involve the inhibition of EBV oncoproteins or cellular genes that 
are critical for virus-associated oncogenesis. 
Liu et al.114 have administered a nucleic acid molecule that can limit tumor cell growth and/or 
cause tumor cell death. The molecule comprises an EBNA1 responsive promoter region 
operatively linked to a gene necessary for viral replication. This method can be used to treat 
and prevent EBV-associated tumors. Franken et al.115 have introduced a suicide gene regulated 
by the expression of EBNA2 into latent EBV-infected cells. Cells expressing EBNA2 are 
demonstrated to be more selectively sensitive to GCV. There is also a complete macroscopic 
regression of established B-cell lymphomas in SCID mice. However, gene therapy suffers from 
the common problem of accurate delivery to the appropriate disease sites. 
5.3 SiRNA therapy 
Therapies using drugs targeted at latent proteins mainly expressing in tumors such as 
LMP1, LMP2A, or EBNA1 are promising. These proteins are critical to the immortalisation 
and proliferation of cells and for evading immune responses. The efficacy of siRNA is 
manifested. Mei et al.116 have constructed a plasmid stably encoding a 21-nt siRNA 
specifically and efficiently interfering with LMP1. The siRNA can induce apoptosis in EBV-
positive lymphoma cells.  
6. Conclusions 
Asymptomatic EBV infection causes a few EBV-associated malignancies and autoimmune 
diseases. The prevention and treatment of these disorders are long-term and arduous. 
Chemotherapy based on chemical agents such as ACV and GCV can effectively inhibit the 
viral DNA polymerase used in the treatment of EBV infection and EBV-associated diseases. 
However, these agents are only effective in lyticly infected cells, but not in latently infected 
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ones. Standard chemotherapy combined with chemical compounds that transform latent 
phase cells into lytic phase cells has apparently increased therapeutic efficiency. Employing 
immunotherapy after chemotherapy also has a prominent effect on prevention and 
treatment. 
Gene and siRNA therapies effectively prevent or inhibit critical genes involved in EBV 
infection. However, they suffer from the same drawback of accurate delivery. Adaptive 
immunotherapy is a promising approach against EBV-associated neoplasias. Based on the 
reactivation and expansion of epitope-specific CTL clones in vitro, the epitope activates and 
increases the immune response against EBV-associated disorders. An effective vaccine that 
prevents primary EBV infection and produce long-lasting protective immunity may 
significantly lessen the occurrence of diseases caused by EBV. Abundant vaccines based on 
membrane glycoproteins or latent proteins against EBV have been developed, and have 
promisingresults. However, an effective vaccine should at least contain promising CD4+ T 
cell and CD8+ cell antigens for both the prevention of symptomatic EBV infection and 
immunotherapy against EBV-associated diseases. 
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